ChemAIRS, an AI-driven retrosynthesis software, was used to investigate the synthesis and process development of Orforglipron, Eli Lilly’s next-generation oral GLP-1 receptor agonist. The proposed synthetics planning strategy optimized its synthesis of key intermediates. With streamlined scale-up reaction conditions, this approach enhances efficiency for commercial production.